دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rheumatic Fever and the American Heart Association: The (Nearly) 100-Year War
Andrea Beaton, Kathryn A. Taubert
doi : 10.1161/CIRCULATIONAHA.120.052711
Circulation. 2021;143:2127–2128
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
Isabelle Johansson, Philip Joseph, Kumar Balasubramanian, John J.V. McMurray, Lars H. Lund, Justin A. Ezekowitz, Deepak Kamath, Khalid Alhabib, Antoni Bayes-Genis, Andrzej Budaj, Antonio L.L. Dans, Anastase Dzudie, Jefferey L. Probstfield, Keith A.A. Fox, Kamilu M. Karaye, Abel Makubi, Bianca Fukakusa, Koon Teo, Ahmet Temizhan, Thomas Wittlinger, Aldo P. Maggioni, Fernando Lanas, Patricio Lopez-Jaramillo, José Silva-Cardoso, Karen Sliwa, Hisham Dokainish, Alex Grinvalds, Tara McCready, Salim Yusuf, and on behalf of the G-CHF Investigators
doi : 10.1161/CIRCULATIONAHA.120.050850
Circulation. 2021;143:2129–2142
Poor health-related quality of life (HRQL) is common in heart failure (HF), but there are few data on HRQL in HF and the association between HRQL and mortality outside Western countries.
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial
Alexandra J. Lansky, Dean J. Kereiakes, Andreas Baumbach, Stephan Windecker, Yasin Hussain, Cody Pietras, Ovidiu Dressler, Ozgu Issever, Michael Curtis, Barry Bertolet, James P. Zidar, Pieter C. Smits, Victor Alfonso Jiménez D?az, Brent McLaurin, Sjoerd Hofma, ?ngel Cequier, Nabil Dib, Edouard Benit, Anthony Mathur, David Brogno, Jacques Berland, Joanna Wykrzykowska, Guy Piegari, Salvatore Brugaletta, Shigeru Saito, Martin B. Leon, and on behalf of the PIONEER III Trial Investigators
doi : 10.1161/CIRCULATIONAHA.120.052482
Circulation. 2021;143:2143–2154
Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel Supreme DES is designed to synchronize early drug delivery within 4 to 6 weeks of implantation, leaving behind a prohealing permanent base layer. Whether the Supreme DES is safe and effective in the short term and can improve long-term clinical outcomes is not known.
Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial
Lars Jakobsen, Evald H. Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Anton B. Villadsen, Steen D. Kristensen, Ole Ahlehoff, Martin K. Christensen, Christian J. Terkelsen, Hans Erik B?tker, Jens Aaroe, Troels Thim, Leif Thuesen, Ahmed Aziz, Ashkan Eftekhari, Rebekka V. Jensen, Nicolaj B. St?ttrup, Jeppe G. Rasmussen, Anders Junker, Svend E. Jensen, Henrik S. Hansen, Lisette O. Jensen
doi : 10.1161/CIRCULATIONAHA.120.052766
Circulation. 2021;143:2155–2165
Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population.
Karnovsky’s Dictum: The Endothelium Is Good-Looking and Smart
Elazer R. Edelman
doi : 10.1161/CIRCULATIONAHA.121.054772
Circulation. 2021;143:2166–2168
Single-Cell RNA Sequencing Uncovers Paracrine Functions of the Epicardial-Derived Cells in Arrhythmogenic Cardiomyopathy
Ping Yuan, Sirisha M. Cheedipudi, Leila Rouhi, Siyang Fan, Lukas Simon, Zhongming Zhao, Kui Hong, Priyatansh Gurha, Ali J. Marian
doi : 10.1161/CIRCULATIONAHA.120.052928
Circulation. 2021;143:2169–2187
Arrhythmogenic cardiomyopathy (ACM) manifests with sudden death, arrhythmias, heart failure, apoptosis, and myocardial fibro-adipogenesis. The phenotype typically starts at the epicardium and advances transmurally. Mutations in genes encoding desmosome proteins, including DSP (desmoplakin), are major causes of ACM.
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Wentong Long, Shubham Soni, Nikole J. Byrne, Amy Barr, Jyoti Singh, Jordan Wong, Taylor Palechuk, Chloe Schneider, Ahmed M. Darwesh, Zaid H. Maayah, John M. Seubert, Khaled Barakat, Jason R.B. Dyck, Peter E. Light
doi : 10.1161/CIRCULATIONAHA.121.053350
Circulation. 2021;143:2188–2204
SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify the underlying molecular mechanisms that afford this protection. Because the induction of the late component of the cardiac sodium channel current (late-INa) is involved in the etiology of heart failure, we investigated whether these drugs inhibit late-INa.
A Silent Arrhythmia: How Would You Manage This Patient?
Jacinthe Boulet, Emmanuelle Massie, Mark Liszkowski
doi : 10.1161/CIRCULATIONAHA.121.054894
Circulation. 2021;143:2205–2207
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars K?ber, Finn Gustafsson, Jens Faber, Julie L. Forman, Jacob E. M?ller, Morten Schou
doi : 10.1161/CIRCULATIONAHA.120.053463
Circulation. 2021;143:2208–2210
How Federal Policy Changes Can Advance the American Heart Association’s Mission to Achieve Health Equity
Keith Churchwell, Emily J. Holubowich
doi : 10.1161/CIRCULATIONAHA.121.055277
Circulation. 2021;143:e1011–e1013
Letter by Mehmood Regarding Article, “Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results”
Muddassir Mehmood
doi : 10.1161/CIRCULATIONAHA.120.052983
Circulation. 2021;143:e1014
Letter by Moayedi et al Regarding Article, “Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results”
Yasbanoo Moayedi, Kyle Runeckles, Juan Duero Posada
doi : 10.1161/CIRCULATIONAHA.120.053104
Circulation. 2021;143:e1015–e1016
Response by Birks et al to Letters Regarding Article, “Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results”
Emma J. Birks, Jesus E. Rame, Christopher Cunningham, Stavros G. Drakos
doi : 10.1161/CIRCULATIONAHA.121.053990
Circulation. 2021;143:e1017–e1018
Correction to: Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
doi : 10.1161/CIR.0000000000000982
Circulation. 2021;143:e1019–e1020
